-
Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons
•
Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led the company’s innovative medicine China business growth project. Zhu has left the role due to “personal reasons,” according to official statements. Before joining Novartis in July 2022, Zhu held a significant position at AstraZeneca (AZ,…
-
MSD’s Q2 2023 Earnings: Keytruda and Gardasil Drive Growth Amid COVID-19 Sales Decline
•
US-based major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has released its financial results for the second quarter of 2023, showing a 7% year-on-year (YOY) growth in worldwide sales, reaching USD 15 billion in constant exchange rates. The pharmaceuticals business reached USD 13.457 billion, up 8% YOY, while Animal…
-
AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer
•
AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license agreement with Pfizer (NYSE: PFE), focusing on a portfolio of preclinical gene therapy programs and related enabling technologies. This strategic deal will provide Alexion with access to several novel adeno-associated virus (capsids), which are crucial…
-
AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales
•
UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the first half of 2023, marking another quarter of robust growth in both top-line and bottom-line figures. Global revenues for the six-month period increased by 4% year-on-year (YOY) in constant exchange rate terms to USD 22.295…
-
AstraZeneca’s Eplontersen Gains Tacit Approval from CDE for ATTR-CM Clinical Study
•
The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ: AZN) injectable eplontersen has been tacitly approved for clinical study in hereditary and wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), aiming to reduce cardiovascular mortality and cardiovascular-related hospitalizations. Eplontersen: An Antisense Oligonucleotide Therapy for ATTR-CMEplontersen, an antisense…
-
Amoy Diagnostics and AstraZeneca Expand Partnership for Companion Diagnostic Development
•
China-based Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685) has announced an additional cooperation agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN), focusing on the development of a companion diagnostic (CDx). This collaboration builds upon a global strategic master collaboration agreement that was first signed at the end of 2021.…
-
Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project
•
This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN), Bayer (ETR: BAYN), and Merck have committed to funding the whole-genome sequencing (WGS) of 250,000 individuals. This significant commitment is in support of the Alliance for Genomic Discovery (AGD), a partnership led by Illumina (NASDAQ:…
-
Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus
•
France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has received marketing approval from the US Food and Drug Administration (FDA) for their codeveloped drug, Beyfortus (nirsevimab). The drug is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in…
-
Chile Expands Financial Coverage for AbbVie’s RSV Prophylaxis Synagis
•
Chile’s Ministry of Health (MINSAL) has announced an immediate expansion in the coverage under its Financial Protection System for High-Cost Diagnosis and Treatments for AbbVie’s (NYSE: ABBV) respiratory syncytial virus (RSV) prophylaxis, Synagis (palivizumab). The biologic drug is now provided free of charge to families of infants weighing under 2.5…
-
Harbour BioMed Reports First-Ever Profit in H1 2023 Interim Financial Results
•
Harbour BioMed (HKG: 2142), a biotech company with operations in Suzhou, China, Cambridge in the US, and the Netherlands, has announced its interim financial results for the period ending June 30, 2023. In a preliminary review of unaudited figures, the company reported a net profit for the first time, expecting…
-
AstraZeneca and Daiichi Sankyo’s Enhertu Gains New Indication Approval in China for HER2-Low Breast Cancer
•
Partners AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) have announced that their co-developed antibody drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), has been granted a new indication approval in China. This marks the drug’s second approval in the country and is specifically for use as a monotherapy in treating…
-
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its anti-interleukin-5 (IL-5) antibody, SHR-1703. The drug candidate is set to be assessed as a treatment for eosinophilic granulomatous polyangiitis, a rare…
-
AstraZeneca’s Dapagliflozin and Metformin Combo Approved by China’s NMPA for Type 2 Diabetes
•
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received market approval from the National Medical Products Administration (NMPA) in China for its fixed dose combination of dapagliflozin and metformin, a treatment for type 2 diabetes. This once-daily compound is now the only sustained-release formulation in China…
-
AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions
•
According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ: AZN) has drafted plans to spin off its China business as a separate entity. Citing “three people familiar with the talks,” the UK-based pharmaceutical giant is said to have begun discussing the idea with bankers…
-
AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based Cholesgen (Shanghai) Co., Ltd. The partnership focuses on the research and development of new therapies for hypercholesterolemia and other metabolic diseases. The collaboration aims to validate genetic drug targets and advance therapeutic molecules into clinical…
-
AstraZeneca’s Soliris Secures Third Indication for Myasthenia Gravis in China
•
UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced that its Soliris (eculizumab), a first-in-class C5 complement inhibitor, has obtained its third indication approval from the National Medical Products Administration (NMPA) in China. This approval allows the use of Soliris to treat adult patients with refractory generalized Myasthenia gravis (gMG)…
-
Baheal Pharmaceutical Partners with RabPharma for Commercialization of RAB001 in China
•
China-based health services and distribution giant Baheal Pharmaceutical Group has announced a strategic partnership with compatriot firm RabPharma. The collaboration focuses on the commercialization of RabPharma’s peptide-drug conjugate (PDC), RAB001, which targets osteonecrosis in mainland China. Financial details of the agreement have not been disclosed. RAB001: A Promising Treatment for…
-
AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment
•
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence (acalabrutinib), a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, in China. The drug previously received conditional marketing approval in the country in March this year, specifically for the treatment of mantle cell lymphoma (MCL) that has…
-
Enhertu, HER2-Targeted ADC, Officially Launched in China for Breast Cancer Treatment
•
Enhertu (trastuzumab deruxtecan), a HER2-targeted antibody-drug conjugate (ADC) co-developed by AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568), has been officially launched in the Chinese market. The drug received marketing approval in China in February 2023 and is now available for the treatment of unresectable or metastatic HER2 positive…
-
AstraZeneca’s Nirsevimab on Track for Priority Review for RSV Prevention in Infants
•
The Center for Drug Evaluation (CDE) website in China indicates that AstraZeneca’s (AZ, NASDAQ: AZN) Beyfortus (nirsevimab) is on course to be awarded priority review status for its use in preventing lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants who are about to enter…
